Head to head
Omnicell vs Veeva Systems
Side-by-side on the measures that matter, with a plain-English read. Full detail: OMCL · VEEV
OMCL
Omnicell
35.21-0.70%
1-year price shape — +16% over the period
Quant Rating D · 57/100
vs
VEEV
Veeva Systems
282.50-0.35%
1-year price shape — -8% over the period
Quant Rating D · 32/100
1-year performance, rebased to 100
Veeva Systems edges it on the scoreable measures. Veeva Systems earns the most per share.
| OMCL | VEEV | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Health Information Services |
| Last price | 35.21 | 282.50 |
| Change today | -0.70% | -0.35% |
| 1-year return | +16.4% | -7.7% |
| Market cap | $1.61B | $45.74B |
| 52-week range | 29.06 – 55.00 | 148.05 – 302.17 |
| Valuation | ||
| P/E (TTM) | 41.92 | 46.31 |
| P/E percentile, own 5-yr range | 38th | 16th |
| P/B | 1.24 | 6.15 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 0.04 | 5.44 |
| Net profit (TTM) | $1.82M | $880.78M |
| Revenue (TTM) | $1.25B | $3.46B |
| Revenue growth (YoY) | +7.4% | +17.6% |
| Gross margin | 44.8% | 75.0% |
| Operating margin | 4.6% | 29.9% |
| Net margin | 3.1% | 29.3% |
| Free cash flow (TTM) | $126.77M | $1.67B |
| Ownership & sentiment | ||
| Institutional ownership | 108.5% | 91.0% |
| Insider activity (12mo) | 18 buy / 32 sell | 29 buy / 18 sell |
| Short interest (% of float) | 7.2% | 3.1% |
| Analyst consensus | 100% buy (7) | 73% buy / 23% hold / 5% sell (22) |
| Analyst price target | $56 (+59%) | $295 (+4%) |
| StockVane view | ||
| StockVane Quant Rating | D (57) | D (32) |
| Company | ||
| Employees | 3,580 | 7,928 |
| Founded | 1992 | 2007 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.